To explore TTN-MT’s predictive role in the prognosis of LUAD patients after ICI therapy, we used a univariate COX regression model and multivariate COX regression model for the follow-up analyses....Compared with TTN-WT LUAD, patients with TTN-MT LUAD had significantly improved OS time [log-rank P = 0.009, HR = 0.43; 95% Cl: 0.2–0.93 (Figure 1C)]. Additionally, LUAD has a higher proportion of clinical benefits of immunotherapy than improved OS time, TTN-MT (Figures 1D, E). Additionally, we found that patients with TTN-MT LUAD had significantly increased pack years in comparison to TTN-WT LUAD (Figure 1F).